Home » Stocks » AKRO

Akero Therapeutics, Inc. (AKRO)

Stock Price: $20.59 USD -1.22 (-5.57%)
Updated Aug 3, 2021 2:16 PM EDT - Market open
Market Cap 746.67M
Revenue (ttm) n/a
Net Income (ttm) -82.41M
Shares Out 34.74M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $20.59
Previous Close $21.80
Change ($) -1.22
Change (%) -5.57%
Day's Open 21.93
Day's Range 20.42 - 21.94
Day's Volume 130,897
52-Week Range 20.42 - 37.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

2 weeks ago - GlobeNewsWire

Akero Therapeutics Inc (NASDAQ: AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of efruxifermin (EFX) in NASH patients with F1-F3 fibrosis have been published in Natu...

3 weeks ago - Benzinga

Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glycemic control Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glyce...

3 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...

1 month ago - GlobeNewsWire

Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with F1-F3 fibrosis. Data ...

1 month ago - Benzinga

Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat Improves Predictive Power for Resolution of NASH with 1-Stage Improvement of Fibrosis Analyses ...

1 month ago - GlobeNewsWire

Akero Therapeutics (AKRO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

1 month ago - Zacks Investment Research

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic s...

2 months ago - GlobeNewsWire

-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution --

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

4 months ago - GlobeNewsWire

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (N...

5 months ago - PRNewsWire

SAN FRANCISCO--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NA...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steat...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential Or...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-a...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines desig...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

10 months ago - PRNewsWire

SAN FRANCISCO, Aug. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

11 months ago - PRNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, PSTX, AZZ, GSK, NKTX, PRSP, TSE ...
1 year ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 7, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 6, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

1 year ago - PRNewsWire

Akero Therapeutics Inc. (NASDAQ: AKRO) has only been public for about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much hi...

1 year ago - 24/7 Wall Street

Akero Therapeutics charged up Wednesday after the biotech company unveiled promising results for a hepatitis treatment.

1 year ago - Investors Business Daily

Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BA...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy result...

1 year ago - PRNewsWire

Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Is (AKRO) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Akero Therapeutics, Inc. (AKRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

1 year ago - PRNewsWire

If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.

1 year ago - The Motley Fool

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

1 year ago - PRNewsWire

Akero Therapeutics Inc (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Akero Therapeutics: A Very Attractive Risk/Reward Opportunity

1 year ago - Seeking Alpha

Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

A first-in-class new drug candidate for the treatment of non-alcoholic steatohepatitis produced some compelling clinical trial results.

1 year ago - The Motley Fool

Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

Other stocks mentioned: DERM, GBT, MRNA
1 year ago - GuruFocus

Akero Therapeutics shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.

2 years ago - Benzinga

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patient... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2019
Stock Exchange
NASDAQ
Ticker Symbol
AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is 60.86, which is an increase of 195.65% from the latest price.

Price Target
$60.86
(195.65% upside)
Analyst Consensus: Strong Buy